Background {#Sec1}
==========

Advanced glycation end products (AGEs) have been implicated in the pathogenesis of both microvascular complications and accelerated atherosclerosis in type 1 diabetes (T1D) \[[@CR1], [@CR2]\]. A proposed mechanism for the deleterious effect of AGEs is engagement of the receptor for AGEs, RAGE, which is a multiligand transmembrane receptor in the immunoglobulin superfamily present on the surface of various cell types in atherosclerotic lesions \[[@CR3]--[@CR5]\]. Two of the AGEs that potentially bind to RAGE are carboxymethyllysine (CML) and methylglyoxal-derived hydroimidazolone-1 (MG-H1) \[[@CR6], [@CR7]\]. Receptor binding leads to activation of monocytes and the vascular endothelium and increases inflammation in the vessel wall \[[@CR8], [@CR9]\]. A mouse cell model indicates that RAGE also mediates AGE-induced macrophage migration \[[@CR10]\].

RAGE has two soluble forms prevalent in human plasma. One created as the membrane bound receptor is cleaved by metalloproteinases \[[@CR11]\], and the other produced by alternative splicing of the RAGE gene \[[@CR12]\]. The latter is known as endogenous secretory RAGE (esRAGE) \[[@CR13]\], and together they constitute plasma soluble RAGE (sRAGE). Estimates indicate that esRAGE accounts for 20--50 % of sRAGE \[[@CR14], [@CR15]\].

It has been postulated that both soluble variants of RAGE work as decoys for AGEs, reducing RAGE signaling and inflammation \[[@CR16]\]. In a mouse model, treatment with intraperitoneal sRAGE suppressed the accelerated atherosclerosis of diabetes \[[@CR17]\]. This suggests that high levels of sRAGE protect against the atherogenic effect of AGEs. Studies in T1D have, however, shown conflicting results. Levels of soluble variants of RAGE both lower \[[@CR18]--[@CR20]\] and higher \[[@CR21]--[@CR23]\] than controls have been demonstrated. Previously, Katakami et al. have found an inverse association between levels of esRAGE and carotid intima media thickness (cIMT) both cross-sectionally \[[@CR18]\] and longitudinally in young adults \[[@CR24]\]. Nin et al., however, showed a positive association between sRAGE and cardiovascular events and all-cause mortality \[[@CR22], [@CR25]\]. The seemingly contradictory results might be due to the different ethnic origin of the study populations \[[@CR26]\], but more likely reflect the complexity of the regulation of the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes. This implies that AGEs or sRAGE alone may not be particularly informative as biomarkers, and an AGE/sRAGE ratio has been proposed as an improvement \[[@CR27]\].

In this study, we aimed to investigate longitudinally whether higher levels of soluble variants of RAGE protect against atherosclerosis development in young patients with T1D compared to healthy controls.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The atherosclerosis and childhood diabetes (ACD) prospective study was initiated in 2006, comprising 314 diabetes patients and 120 controls, all between 8 and 18 years old, from the South East health region of Norway. The non-diabetic controls were mainly classmates of the diabetes patients. The details of the cohort and inclusion process have previously been described \[[@CR28]\]. From 2011 to 2013, the participants were encouraged to attend a 5-year follow-up, and 80 % agreed. An additional 38 control subjects were also enrolled at this time.

Both at baseline and at follow-up, blood samples were taken in the morning between 0800 and 1000 a.m. after an overnight fast. This was followed by carotid ultrasound and a clinical examination.

All parents and participants over 18 years old have given their written informed consent. The protocol, both at baseline and follow-up has been approved by the Norwegian Regional Committee for Research Ethics, and the study has been conducted according to the Declaration of Helsinki.

Laboratory methods {#Sec4}
------------------

All blood samples were centrifuged at 2500×*g* for 10 min immediately after venipuncture and stored at −80 °C until analysis. Serum sRAGE and esRAGE were measured using enzyme-linked immunosorbent assay (ELISA) kits (Quantikine, R&D Systems, Minneapolis, MN, USA and B-Bridge International Inc., Cupertino, CA, USA respectively) according to the manufacturer's instructions. The inter-assay coefficients of variation (CV) in our laboratory were 5.8 % for sRAGE and 5.7 % for esRAGE. At baseline 411 participants (299 diabetes patients, 112 controls) had valid measurements. At follow-up 369 (241 diabetes patients and 128 controls) were tested. 318 participants (231 diabetes patients and 87 controls) had measurements at both baseline and follow-up. All samples from both timepoints were measured in the same run to avoid bias due to assay variability.

MG-H1 and CML were measured by dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) as previously described in detail \[[@CR29]--[@CR31]\].

Images of the common carotid arteries (CCAs) at baseline were obtained using a Siemens Acuson Sequoia 512 (Siemens Acuson; Mountain View, CA, USA) ultrasound scanner equipped with a linear array 14 MHz transducer. Further details have been described previously \[[@CR28]\]. At follow-up, the images of the CCAs were obtained using a Zonare Z-one ULTRA (Zonare Medical Systems; Mountain View, CA, USA) ultrasound scanner equipped with a linear array 8 MHz transducer. The cIMT measurements were performed using M'Ath 3.2.0 (Intelligence in Medical Imaging; Paris, France). All cIMT measurements were from the far wall in end-diastole. Blood pressure for calculating Young's modulus was assessed using a standard oscillometric device over the brachial artery.

CRP was determined by high sensitivity ELISA (DRG Instruments GmbH, Germany) with a detection limit of 0.1 mg/L. The inter-assay CV was \<5 %.

HbA1c was measured at a DCCT-standardized laboratory using high performance liquid chromatography (Variant; Bio-Rad, Richmond, CA, USA), CV \<3 %. Other routine laboratory analyses were performed by conventional methods.

Statistical analysis {#Sec5}
--------------------

Demographic and clinical data are presented as either proportions, means with their standard deviations (SD) or medians with the 25th and 75th percentile. Differences in continuous variables between groups were tested with the Student *t* test, alternatively the Mann--Whitney *U*-test for non-normally distributed data. Correlation analyses between continous variables were performed using Pearson's correlation coefficient (r) for normally distributed data, or otherwise Spearman's rho (*ρ*). Univariate linear regression analysis was performed to identify associations between sRAGE and esRAGE as exposure variables and surrogate markers of atherosclerosis as outcome variables. Only variables with significant relationships with both the exposure and the outcome variables were considered as possible confounders and included in a multivariate analysis. Adjustment for multiple confounding factors was performed using multivariate linear regression analysis with a manual backward elimination procedure. CRP was log~e~-transformed to achieve normally distributed residuals. A significance level of 5 % was used.

In addition, multivariate linear regression analysis with a manual backward elimination procedure was performed to identify predictors for soluble variants of RAGE at follow-up. Any variable with a p value \<0.20 from the univariate analysis was considered a candidate for the multivariate model. All statistical analyses were performed using the SPSS software package for Mac, version 19.0 (SPSS, Chicago, IL, USA).

Results {#Sec6}
=======

Most of the diabetes patients (97 %) were on intensive insulin treatment using insulin pumps or \>4 insulin injections a day. At baseline, comparison with the Norwegian Childhood Diabetes Registry showed that our cohort was a representative sample of the young T1D population in Norway regarding gender, stage of puberty, HbA1c, blood pressure and lipid status \[[@CR28]\]. Due to exclusion of participants under 8 years of age, the patients in our cohort were slightly older, had longer diabetes duration, higher body mass index (BMI) and were more frequently pump users than the rest of the Norwegian children and adolescents with diabetes. The clinical and metabolic characteristics of the patients at baseline and follow-up are shown in Table [1](#Tab1){ref-type="table"}. The diabetic patients had higher body weight, blood pressure and increased serum lipid levels compared to the control subjects both at baseline and at follow-up.Table 1Clinical and metabolic characteristicsBaseline5 year follow-upDiabetes (n = 299)Controls (n = 112)p valueDiabetes (n = 241)Controls (n = 128)p valueDiabetes duration (years)^a^5.1 (2.9, 7.7)9.6 (7.5, 12.6)Insulin pump users (%)53.361.3Age (years)13.7 (2.8)13.4 (2.5)0.20718.7 (2.8)18.7 (2.9)0.895Girls, n (%)150 (50.2)64 (57.1)0.224129 (53.5)72 (56.3)0.661Height (cm)160.5 (14.4)157.6 (13.3)0.060171.2 (9.1)172.1 (9.2)0.383Weight (kg)54.8 (16.7)48.5 (13.2)\<0.00171.0 (14.6)66.9 (12.5)0.006BMI (kg/m^2^)20.8 (3.9)19.2 (3.1)\<0.00124.1 (4.3)22.5 (3.4)\<0.001Waist circumference (cm)71.1 (10.0)66.8 (6.6)\<0.00179.0 (9.6)75.5 (8.2)\<0.001Systolic blood pressure (mmHg)101 (10.1)98 (10)0.025112 (11)111 (10)0.656Diastolic blood pressure (mmHg)60 (8)58 (7)0.01770 (8)68 (8)0.024HbA1c (%) \[mmol/mol, SD\]8.4 (1.2) \[68, 13.1\]5.3 (0.3) \[34, 3.3\]\<0.0019.0 (1.4) \[75, 15.3\]5.2 (0.3) \[33, 3.3\]\<0.001Total cholesterol (mmol/L)4.6 (0.8)4.3 (0.7)0.0014.8 (1.0)4.4 (1.0)0.001HDL (mmol/L)1.8 (0.4)1.7 (0.4)0.0481.6 (0.5)1.6 (0.4)0.161LDL (mmol/L)2.5 (0.7)2.3 (0.7)0.0162.7 (0.8)2.5 (0.8)0.014Triglycerides (mmol/L)^a^0.7 (0.5, 0.9)0.7 (0.5, 0.9)0.3670.9 (0.6, 1.3)0.8 (0.6, 1.0)0.024Apolipoprotein B (g/L)0.74 (0.19)0.66 (0.17)\<0.0010.90 (0.26)0.79 (0.23)\<0.001Apolipoprotein A1 (g/L)1.55 (0.28)1.44 (0.33)0.0011.56 (0.31)1.48 (0.27)0.006ApoB/ApoA10.5 (0.2)0.5 (0.3)0.6980.6 (0.2)0.5 (0.2)0.025Urine albumin/creatinine (mg/mmol)^a^0.70 (0.40, 1.30)0.63 (0.36, 1.33)0.6880.65 (0.30, 1.55)0.34 (0.19, 0.90)0.001Mean values (SD)^a^Median (25th and 75th percentile)

The results from the sRAGE and esRAGE assays and the measurements of surrogate markers of atherosclerosis are presented in Table [2](#Tab2){ref-type="table"}. We found no difference in soluble variants of RAGE between the groups, except for lower levels of esRAGE in the diabetes group at baseline. As for cIMT and Young's modulus, we found no significant differences between the groups. CRP was significantly elevated in the diabetes group both at baseline \[[@CR32]\] and at follow-up.Table 2Soluble RAGE and surrogate markers of atherosclerosisBaseline5 year follow-upDiabetesControlsp valueDiabetesControlsp valuesRAGE (pg/ml)1664 (602)1773 (574)0.1001578 (589)1585 (561)0.909esRAGE (ng/ml)0.36 (0.16)0.42 (0.16)\<0.0010.33 (0.21)0.33 (0.13)0.810cIMT (mm)0.45 (0.05)0.44 (0.04)0.0670.51 (0.05)0.51 (0.06)0.324Young's modulus (kPa)13.7 (2.8)13.4 (2.5)0.20718.7 (2.8)18.7 (2.9)0.895CRP (mg/l)^a^0.50 (0.27, 1.84)0.31 (0.19, 0.67)\<0.0011.16 (0.43, 3.64)0.69 (0.28, 2.00)0.002Mean values (SD)^a^Median (25th and 75th percentile)

The levels of sRAGE and esRAGE correlated strongly, both in the diabetes and the control group (Table [3](#Tab3){ref-type="table"}). In the diabetes group, the boys had significantly higher sRAGE both at baseline \[1752 (SD = 609) vs. 1576 (SD = 584) pg/ml, p = 0.011\] and at follow-up \[1682 (SD = 609) vs. 1487 (SD = 557) pg/ml, p = 0.010\] as well as higher esRAGE at baseline \[0.39 (SD = 0.17) vs. 0.34 (SD = 0.15) ng/ml, p = 0.005\] than the girls. These differences disappeared when excluding the girls using oral contraceptives from the analysis.Table 3Coefficients of correlation (Pearson), all with p \< 0.001Diabetes groupControl groupesRAGE baselineesRAGE follow-upsRAGE baselineesRAGE baselineesRAGE follow-upsRAGE baselineesRAGE follow-up0.39610.6361sRAGE baseline0.8000.29510.7750.5971sRAGE follow-up0.5930.5100.6380.4580.8280.620

At baseline, there was a weak negative correlation between HbA1c and sRAGE (r = −0.148, p = 0.011) and esRAGE (r = −0.137, p = 0.018). There were no significant correlations with HbA1c at follow-up or in the control group at any time point.

Natural progression of sRAGE and esRAGE {#Sec7}
---------------------------------------

There was a decline in sRAGE and esRAGE levels with increasing age. Figure [1](#Fig1){ref-type="fig"} shows levels of sRAGE in diabetes patients and controls. For illustrative purposes, values from each patient at both baseline and follow-up are included. The graphs for esRAGE as well as for both soluble variants of RAGE when separated by gender showed similar patterns. There was no decline in the levels of either soluble variant of RAGE across the five Tanner stages of puberty.Fig. 1Mean sRAGE and age. Values in diabetes patients (*grey line)* and controls (*dotted line*). The figure includes two values from each participant, one at baseline and one at follow-up

To determine whether this relationship with age was confounded by other factors, we performed regression analyses. At baseline, the association between age and esRAGE remained significant after controlling for the confounding effect of CRP in the diabetes group (B = −0.009, R^2^ = 0.082 and p = 0.009) and in girls with diabetes (B = −0.012, R^2^ = 0.123 and p = 0.008). Also, sRAGE was significantly associated with age in the control group (B = −47.1, R^2^ = 0.081 and p = 0.033, controlling for MG-H1), in girls with diabetes (B = −61.6, R^2^ = 0.154 and p = 0.001, controlling for CRP) and in control girls (B = −99.1, R^2^ = 0.154 and p = 0.001, no confounding variables). At follow-up, esRAGE was not associated with age in any group. There was, however, significant associations between sRAGE and age in the diabetes group (B = −51.5, R^2^ = 0.131 and p \< 0.001, controlling for CRP), in boys with diabetes (B = −57.8, R^2^ = 0.071 and p = 0.004, no confounding variables) and in girls with diabetes (B = −45.5, R^2^ = 0.152 and p = 0.016, controlling for CRP). When identifying predictors of esRAGE or sRAGE in the different groups, age was only significant for sRAGE at follow-up in the diabetes group.

Soluble variants of RAGE and atherosclerosis {#Sec8}
--------------------------------------------

In multiple regression analyses we found significant associations between soluble variants of RAGE and the surrogate markers of atherosclerosis cIMT and CRP in the diabetes group. These are presented in Table [4](#Tab4){ref-type="table"}. There were no significant associations in the control group, and there were no significant associations involving Young's modulus in either group.Table 4Significant associations in the diabetes groupIndependent variableDependent variableBeta valueSEp valueR^2^Confounding variablesBaseline esRAGEFollow-up cIMT0.0740.0230.0010.141Gender, waist circumference, BMIBaseline sRAGEFollow-up cIMT1.4 × 10^−5^6.2 × 10^−6^0.0270.116Gender, waist circumference, ApoBBaseline sRAGEFollow-up CRP−3.3 × 10^−4^1.4 × 10^−4^0.0170.269Height, medication, BMI

We also analyzed delta values (follow-up minus baseline). We found no significant associations between baseline variants of soluble RAGE and delta CRP in either patient group. Due to different measurement techniques applied at each time point, we were unable to evaluate delta values for cIMT and Young's modulus. Delta sRAGE and delta esRAGE were not correlated with either delta HbA1c, delta LDL or delta BMI.

AGE/soluble variants of RAGE ratios {#Sec9}
-----------------------------------

At baseline, levels of MG-H1 were significantly increased in the diabetes group compared to controls, 154.4 (SD = 40.8) vs. 142.8 (SD = 35.5) U/ml, p = 0.008. There was no significant difference in CML, 18.0 (SD = 4.4) vs. 17.3 (SD = 5.7) U/ml, p = 0.152. All possible AGE/soluble variants of RAGE ratios at baseline were significantly increased in the diabetes patients compared to controls (Table [5](#Tab5){ref-type="table"}). In multivariate analyses, there were no significant associations between AGE/soluble variants of RAGE ratios at baseline and surrogate markers of atherosclerosis 5 years later.Table 5AGE/soluble RAGE ratiosRatioDiabetes patientsControlsp valueMG-H1/sRAGE0.099 (0.071, 0.124)0.083 (0.058, 0.117)0.006MG-H1/esRAGE461 (335,624)332 (248,480)\<0.001CML/sRAGE0.012 (0.008, 0.015)0.010 (0.007, 0.013)0.005CML/esRAGE53.4 (39.8, 72.4)38.1 (28.6, 58.6)\<0.001Median (25th, 75th percentile)

Discussion {#Sec10}
==========

The main findings in this study are the relationships between the soluble variants of RAGE and surrogate markers of atherosclerosis. Our analyses do not indicate a protective effect of high levels of sRAGE or esRAGE against atherosclerosis development measured by cIMT. In fact, in the diabetes group we found the opposite, that high levels of both sRAGE and esRAGE at baseline are significantly associated with higher cIMT 5 years later. This is in line with the studies by Nin et al. \[[@CR22], [@CR25]\]. On the other hand, baseline sRAGE was significantly negatively associated with CRP, indicating a protective effect against inflammation. We found no significant associations between soluble variants of RAGE and any measure of atherosclerosis in the control group.

We have demonstrated a reduction in values of both sRAGE and esRAGE in the teens and early twenties, regardless of diabetes, gender, or pubertal stage. The association with age remained significant in several groups when controlling for confounding factors, particularly in girls. A similar reduction with increasing age has been shown in women below the age of 35 compared to older subjects \[[@CR33]\]. Komosinska-Vassev et al. have also shown decreasing esRAGE values with increasing age in subjects without significant disease, particularly in women \[[@CR34]\]. The participants in our study were young and healthy, apart from T1D. The fact that we did not find an association between T1D and the reduction in sRAGE or esRAGE values suggests that this is a normal physiologic development. Most studies, however, show a significant relationship between soluble variants of RAGE and disease states \[[@CR35]\]. High levels of sRAGE are associated with healthy aging \[[@CR36]\], but whether sRAGE is protective against disease, reduced in disease, or both, is unknown.

The strong correlation between baseline and follow-up values of both sRAGE and esRAGE indicate that changes in levels of soluble variants of RAGE over time in each patient are generally small. We also found strong correlations between sRAGE and esRAGE both at baseline and follow-up. This suggests that esRAGE constitutes a large proportion of the measured sRAGE and consequently that the cleaved form of RAGE is less prevalent. This is in contrast to most other studies, where esRAGE is estimated to constitute only 20 % of sRAGE \[[@CR11], [@CR14], [@CR37], [@CR38]\]. A possible explanation is that our subjects are younger and healthier than in the previous studies. This is supported by the only study that has assessed the levels of sRAGE and esRAGE using comparable immunoassays \[[@CR15]\]. Higher levels of esRAGE compared to sRAGE in youth is reasonable since RAGE amplifies inflammation \[[@CR9]\]. Older patients with more pronounced atherosclerosis or other inflammatory diseases would express more RAGE on the cell surface and subsequently release more cleaved RAGE into the circulation \[[@CR39]\].

The regulation of the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes is only partly understood. RAGE is subject to regulated intramembrane proteolysis by ADAM10 (a disintegrin and metalloproteinase 10), shedding the cleaved variant of sRAGE in a process dependent on intracellular calcium levels \[[@CR40]\]. Shedding can also be induced by activation of G protein-coupled receptors \[[@CR41]\]. As for esRAGE, engagement of RAGE by methylglyoxal-modified human serum albumin stimulated production of RAGE and esRAGE to a similar extent in human umbilical vein endothelial cells. Interestingly, engagement of RAGE by carboxymethyllysine-modified human serum albumin more selectively stimulated production of RAGE \[[@CR42]\]. Ohe et al. have shown that elements in exon 9B of the RAGE gene can modulate the ratio of RAGE/esRAGE production \[[@CR43]\]. Levels of sRAGE are associated with albuminuria, indicating that kidney function is important for esRAGE excretion \[[@CR38]\]. Still, much is yet left to discover about the production and excretion of the soluble variants of RAGE. Even though sRAGE in our study was negatively associated with CRP 5 years later, this does not necessarily imply a causal relationship. The finding indicates a protective effect, but as inflammation most likely alters the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes in a still unpredictable fashion, sound conclusions are difficult to reach.

The AGE/sRAGE ratio has been proposed as an improved biomarker for the AGE-RAGE-sRAGE axis \[[@CR27]\]. A higher ratio is associated with pre-eclampsia in women with T1D \[[@CR44]\], and we also found higher ratios in diabetes patients compared to controls in this study. However, we found no significant associations with surrogate markers of atherosclerosis, rendering the ratios less useful than sRAGE alone. Furthermore, the ratios are hardly easier to interpret than the separate factors, as the influence of other AGEs, membrane bound RAGE, production and excretion of sRAGE and esRAGE are still unknown.

Strengths and limitations {#Sec11}
-------------------------

The strengths of this study include the prospective design, relatively large cohort of diabetes patients and controls and different surrogate markers of atherosclerosis. There are of course also limitations. Non-invasive measurement of atherosclerosis in children and young adults have several inherent shortcomings. Only cIMT and CRP are accepted surrogate markers of atherosclerosis, and best documented in adults \[[@CR45]\]. Young's modulus is not the gold standard for measuring arterial stiffness, which introduces some uncertainty. It is debatable whether AGE's in the concentration found in vivo actually are important ligands for RAGE, and there are several other classes of ligands for RAGE not considered in this study, including the proteins S100/calgranulin and high mobility group box 1 (HMGB1) and others \[[@CR46], [@CR47]\]. As long as the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes are insufficiently understood, the data must be interpreted with caution.

Conclusions {#Sec12}
===========

In this study, we have shown a possible protective effect of high levels of sRAGE on inflammation, but not on arterial stiffness or wall thickness, in this cohort of adolescents and young adults with T1D. We have also shown an age-associated decline in values of both sRAGE and esRAGE in the teens and early twenties of both T1D patients and healthy control subjects.
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